Acadian Asset Management’s Haemonetics HAE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $898K | Buy |
15,989
+11,021
| +222% | +$718K | ﹤0.01% | 1194 |
|
|
2025
Q4 | $397K | Buy |
4,968
+3,235
| +187% | +$217K | ﹤0.01% | 1370 |
|
|
2025
Q3 | $83K | Buy |
+1,733
| New | +$107K | ﹤0.01% | 1558 |
|
|
2024
Q4 | – | Sell |
-875
| Closed | -$70K | – | 1843 |
|
|
2024
Q3 | $70K | Buy |
+875
| New | +$70.7K | ﹤0.01% | 1710 |
|
|
2023
Q4 | – | Sell |
-1,915
| Closed | -$171K | – | 1721 |
|
|
2023
Q3 | $171K | Sell |
1,915
-6,589
| -77% | -$588K | ﹤0.01% | 1220 |
|
|
2023
Q2 | $724K | Sell |
8,504
-7,743
| -48% | -$655K | ﹤0.01% | 962 |
|
|
2023
Q1 | $1.34M | Buy |
16,247
+530
| +3% | +$42.9K | 0.01% | 804 |
|
|
2022
Q4 | $1.23M | Buy |
15,717
+14,666
| +1,395% | +$1.18M | 0.01% | 794 |
|
|
2022
Q3 | $77K | Buy |
+1,051
| New | +$75.5K | ﹤0.01% | 1421 |
|
|
2021
Q2 | – | Sell |
-329
| Closed | -$37K | – | 2081 |
|
|
2021
Q1 | $37K | Hold |
329
| – | – | ﹤0.01% | 1888 |
|
|
2020
Q4 | $39K | Hold |
329
| – | – | ﹤0.01% | 1996 |
|
|
2020
Q3 | $29K | Sell |
329
-47,582
| -99% | -$4.16M | ﹤0.01% | 1991 |
|
|
2020
Q2 | $4.29M | Sell |
47,911
-36,638
| -43% | -$3.7M | 0.02% | 518 |
|
|
2020
Q1 | $8.43M | Buy |
84,549
+7,351
| +10% | +$797K | 0.05% | 284 |
|
|
2019
Q4 | $8.87M | Sell |
77,198
-28,441
| -27% | -$3.44M | 0.04% | 330 |
|
|
2019
Q3 | $13.3M | Sell |
105,639
-114,146
| -52% | -$14.5M | 0.06% | 280 |
|
|
2019
Q2 | $26.4M | Sell |
219,785
-178,857
| -45% | -$17.6M | 0.13% | 165 |
|
|
2019
Q1 | $34.9M | Sell |
398,642
-275,765
| -41% | -$25.1M | 0.15% | 146 |
|
|
2018
Q4 | $67.5M | Sell |
674,407
-105,091
| -13% | -$11M | 0.33% | 85 |
|
|
2018
Q3 | $89.3M | Sell |
779,498
-108,599
| -12% | -$11.2M | 0.37% | 76 |
|
|
2018
Q2 | $79.6M | Buy |
888,097
+196,154
| +28% | +$16.6M | 0.34% | 77 |
|
|
2018
Q1 | $50.6M | Buy |
691,943
+167,175
| +32% | +$11.5M | 0.22% | 104 |
|
|
2017
Q4 | $30.5M | Buy |
524,768
+263,432
| +101% | +$13.9M | 0.13% | 145 |
|
|
2017
Q3 | $11.7M | Buy |
261,336
+141,753
| +119% | +$5.89M | 0.05% | 263 |
|
|
2017
Q2 | $4.72M | Buy |
119,583
+57,943
| +94% | +$2.38M | 0.02% | 411 |
|
|
2017
Q1 | $2.5M | Sell |
61,640
-6,515
| -10% | -$254K | 0.01% | 565 |
|
|
2016
Q4 | $2.74M | Buy |
68,155
+52,879
| +346% | +$1.99M | 0.01% | 524 |
|
|
2016
Q3 | $553K | Sell |
15,276
-25,606
| -63% | -$879K | ﹤0.01% | 796 |
|
|
2016
Q2 | $1.19M | Buy |
+40,882
| New | +$1.24M | 0.01% | 606 |
|
Other funds holding HAE
VPM
VCM
RRAM
Acadian Asset Management's HAE Position: Q1 2026 in Review
Acadian Asset Management increased its Haemonetics (HAE) stake by 222% in Q1 2026, buying an estimated $718K and bringing the position to 15,989 shares worth $898K. The position accounts for ﹤0.01% of the portfolio, ranked #1194.
Acadian Asset Management first reported a position in HAE in Q2 2016 and has held it in 29 quarters since. The position peaked at $89.3M in Q3 2018. 324 funds tracked by Wall St. Rank hold HAE as of Q1 2026.
- Acadian Asset Management held 15,989 shares of Haemonetics worth $898K as of Q1 2026.
- Acadian Asset Management bought 11,021 Haemonetics shares in Q1 2026, an estimated $718K.
- Haemonetics made up ﹤0.01% of Acadian Asset Management's portfolio in Q1 2026, its #1194 holding.
- Acadian Asset Management first reported a position in Haemonetics in Q2 2016 and has held it in 29 quarters since.
- Acadian Asset Management's Haemonetics position peaked at $89.3M in Q3 2018.
- 324 funds tracked by Wall St. Rank held Haemonetics as of Q1 2026.
Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.